Defensins as anti-inflammatory compounds and mucosal adjuvants

Future Microbiology

Volumn 5, Issue 1, 2010, Pages 99-113

  Kohlgraf, Karl G ^a   Pingel, Lindsey C ^a   Dietrich, Deborah E ^a   Brogden, Kim A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Adjuvant; Defensin; Innate immunity; Mucosal immunity; Oral inflammation

Indexed keywords

ALPHA DEFENSIN; ANTIINFLAMMATORY AGENT; BETA DEFENSIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; EPIDERMAL GROWTH FACTOR RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; HEMAGGLUTININ; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; KEYHOLE LIMPET HEMOCYANIN; MELITTIN; MITOGEN ACTIVATED PROTEIN KINASE 3; PLASMID DNA; STAT1 PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TETANUS TOXOID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; BETA SHEET; CYTOKINE PRODUCTION; DENDRITIC CELL; DISSOCIATION CONSTANT; HUMAN; IMMUNOGENICITY; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; NONHUMAN; NOSE CAVITY; ORAL MUCOSAL DISEASE; PHAGOCYTOSIS; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ALPHA-DEFENSINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BETA-DEFENSINS; HUMANS; MICE;

MUS;

EID: 75849147159     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.104     Document Type: Review

References (118)

1. Cocolin L, Diez A, Urso R et al.: Optimization of conditions for profiling bacterial populations in food by culture-independent methods. Int. J. Food Microbiol. 120, 100-109 (2007).
2. Takahashi H, Konuma H, Hara-Kudo Y: Development of a quantitative real-time PCR method to enumerate total bacterial counts in ready-to-eat fruits and vegetables. J. Food Prot. 69, 2504-2508 (2006).
3. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE: Defining the normal bacterial flora of the oral cavity. J. Clin. Microbiol. 43, 5721-5732 (2005).
4. Vianna ME, Conrads G, Gomes BP, Horz HP: T-RFLP-based mcrA gene analysis of methanogenic archaea in association with oral infections and evidence of a novel Methanobrevibacter phylotype. Oral Microbiol. Immunol. 24, 417-422 (2009).
5. Tanner AC, Paster BJ, Lu SC et al.: Subgingival and tongue microbiota during early periodontitis. J. Dent. Res. 85, 318-323 (2006).
6. Hull MW, Chow AW: Indigenous microflora and innate immunity of the head and neck. Infect. Dis. Clin. North Am. 21, 265-282 (2007).
7. Soderblom T, Oxhamre C, Torstensson E, Richter-Dahlfors A: Bacterial protein toxins and inflammation. Scand. J. Infect. Dis. 35, 628-631 (2003).
8. Han J, Ulevitch RJ: Limiting inflammatory responses during activation of innate immunity. Nat. Immunol. 6, 1198-1205 (2005).
9. Henson PM: Dampening inflammation. Nat. Immunol. 6, 1179-1181 (2005).
10. Mayer L, Shao L: Therapeutic potential of oral tolerance. Nat. Rev. Immunol. 4, 407-419 (2004).
11. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ: Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. 22, 181-215 (2004).
12. Yang D, Biragyn A, Kwak LW, Oppenheim JJ: Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 23, 291-296 (2002).
13. Yang D, Chertov O, Oppenheim JJ: The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell. Mol. Life Sci. 58, 978-989. (2001).
14. Venkataraman N, Cole AL, Ruchala P et al.: Reawakening retrocyclins: ancestral human defensins active against HIV 1. PLoS Biol. 7, e95 (2009).
15. Menendez A, Finlay B: Defensins in the immunology of bacterial infections. Curr. Opin. Immunol. 19, 385-391 (2007).
16. Radek K, Gallo R: Antimicrobial peptides: natural effectors of the innate immune system. Semin. Immunopathol. 29, 27-43 (2007).
17. Diamond G, Beckloff N, Ryan LK: Host defense peptides in the oral cavity and the lung: similarities and differences. J. Dent. Res. 87, 915-927 (2008).
18. Rehaume LM, Hancock RE: Neutrophil-derived defensins as modulators of innate immune function. Crit. Rev. Immunol. 28, 185-200 (2008).
19. Lehrer RI: Primate defensins. Nat. Rev. Microbiol. 2, 727-738 (2004).
20. Selsted ME, Ouellette AJ: Mammalian defensins in the antimicrobial immune response. Nat. Immunol. 6, 551-557 (2005).
21. Bissell J, Joly S, Johnson GK et al.: Expression of b defensins in gingival health and in periodontal disease. J. Oral Pathol. Med. 33, 278-285 (2004).
22. Feng Z, Dubyak GR, Lederman MM, Weinberg A: Cutting edge: human b defensin 3 - a novel antagonist of the HIV 1 coreceptor CXCR4. J. Immunol. 177, 782-786 (2006).
23. Hazrati E, Galen B, Lu W et al.: Human a- and b defensins block multiple steps in herpes simplex virus infection. J. Immunol. 177, 8658-8666 (2006).
24. Joly S, Maze C, McCray PB Jr, Guthmiller JM: Human b defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J. Clin. Microbiol. 42, 1024-1029 (2004).
25. Froy O: Regulation of mammalian defensin expression by Toll-like receptor-dependent and independent signalling pathways. Cell. Microbiol. 7, 1387-1397 (2005).
26. Vora P, Youdim A, Thomas LS et al.: β defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J. Immunol. 173, 5398-5405 (2004).
27. Wehkamp J, Harder J, Wehkamp K et al.: NF-kB- and AP-1-mediated induction of human b defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun. 72, 5750-5758 (2004).
28. Ogushi K, Wada A, Niidome T et al.: Gangliosides act as co-receptors for Salmonella enteritidis FliC and promote FliC induction of human b defensin-2 expression in Caco-2 cells. J. Biol. Chem. 279, 12213-12219 (2004).
29. Krisanaprakornkit S, Kimball JR, Dale BA: Regulation of human b defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NF-kB transcription factor family. J. Immunol. 168, 316-324 (2002).
30. Albanesi C, Fairchild HR, Madonna S et al.: IL-4 and IL-13 negatively regulate TNF a- and IFN g-induced b defensin expression through STAT 6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J. Immunol. 179, 984-992 (2007).
31. Menzies BE, Kenoyer A: Signal transduction and nuclear responses in Staphylococcus aureus-induced expression of human β defensin 3 in skin keratinocytes. Infect. Immun. 74, 6847-6854 (2006).
32. Sorensen OE, Thapa DR, Rosenthal A, Liu L, Roberts AA, Ganz T: Differential regulation of b defensin expression in human skin by microbial stimuli. J. Immunol. 174, 4870-4879 (2005).
33. Boughan PK, Argent RH, Body-Malapel M et al.: Nucleotide-binding oligomerization domain-1 and epidermal growth factor receptor: critical regulators of b defensins during Helicobacter pylori infection. J. Biol. Chem. 281, 11637-11648 (2006).
34. Biragyn A, Ruffini PA, Leifer CA et al.: Toll-like receptor 4-dependent activation of dendritic cells by b defensin 2. Science 298, 1025-1029 (2002).
35. Lytvyn D, Zhuravel E, Markeeva N, Soldatkina M, Dudchenko T, Pogrebnoy P: Involvement of human β defensin-2 in intracellular signaling: in vitro study. Exp. Oncol. 28, 198-202 (2006).
36. Stroinigg N, Srivastava MD: Modulation of Toll-like receptor 7 and LL-37 expression in colon and breast epithelial cells by human β defensin-2. Allergy Asthma Proc. 26, 299-309 (2005).
37. Niyonsaba F, Ushio H, Nagaoka I, Okumura K, Ogawa H: The human βdefensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J. Immunol. 175, 1776-1784 (2005).
38. Shi J, Aono S, Lu W et al.: A novel role for defensins in intestinal homeostasis: regulation of IL-1b secretion. J. Immunol. 179, 1245-1253 (2007).
39. Miles K, Clarke DJ, Lu W et al.: Dying and necrotic neutrophils are anti-inflammatory secondary to the release of a defensins. J. Immunol. 183, 2122-2132 (2009).
40. Pingel LC, Kohlgraf KG, Hansen CJ et al.: Human b defensin 3 binds to hemagglutinin B (rHagB), a non-fimbrial adhesin from Porphyromonas gingivalis, and attenuates a pro-inflammatory cytokine response. Immunol. Cell Biol. 86, 643-649 (2008).
41. Biragyn A: Defensins - non-antibiotic use for vaccine development. Curr. Protein Pept. Sci. 6, 53-60 (2005).
42. Dhople V, Krukemeyer A, Ramamoorthy A: The human b defensin-3, an antibacterial peptide with multiple biological functions. Biochim. Biophys. Acta 1758, 1499-1512 (2006).
43. Bohling A, Hagge SO, Roes S et al.: Lipid-specific membrane activity of human β defensin-3. Biochemistry (Mosc.) 45, 5663-5670 (2006).
44. Dietrich DE, Xiao X, Dawson DV et al.: Human a- and b defensins bind to immobilized adhesins from Porphyromonas gingivalis. Infect. Immun. 76, 5714-5720 (2008).
45. Motzkus D, Schulz-Maronde S, Heitland A et al.: The novel b defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo. FASEB J. 20, 1701-1702 (2006).
46. Giesemann T, Guttenberg G, Aktories K: Human a defensins inhibit Clostridium difficile toxin B. Gastroenterology 134, 2049-2058 (2008).
47. Kim C, Gajendran N, Mittrucker HW et al.: Human a defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc. Natl Acad. Sci. USA 102, 4830-4835 (2005).
48. Kim C, Slavinskaya Z, Merrill AR, Kaufmann SH: Human a defensins neutralize toxins of the mono-ADP-ribosyltransferase family. Biochem. J. 399, 225-229 (2006).
49. Wang W, Mulakala C, Ward SC et al.: Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin. J. Biol. Chem. 281, 32755-32764 (2006).
50. Wang W, Cole AM, Hong T, Waring AJ, Lehrer RI: Retrocyclin, an antiretroviral θ defensin, is a lectin. J. Immunol. 170, 4708-4716 (2003).
51. Owen SM, Rudolph DL, Wang W et al.: RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 20, 1157-1165 (2004).
52. Owen SM, Rudolph D, Wang W et al.: A θ defensin composed exclusively of d-amino acids is active against HIV 1. J. Pept. Res. 63, 469-476 (2004).
53. Gallo SA, Wang W, Rawat SS et al.: θ defensins prevent HIV 1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J. Biol. Chem. 281, 18787-18792 (2006).
54. Pingel LC, Srikantha RN, Belanger M, Progulske-Fox A, Kurago Z, Brogden KA: HBD3 inhibits Porphyromonas gingivalis rHagB binding to keratinocytes/dendritic cells. Presented at: 87th General Session IADR/ AADR/CADR. Miami Beach Convention Center, FL, USA, 1-4 April 2009.
55. Dietrich DE, Belanger M, Progluske-Fox A, Kurago Z, Brogden KA: HBD3 inhibits Porphyromonas gingivalis Hemagglutinin B binding to dendritic cells. Presented at: 87th General Session IADR/AADR/CADR. Miami Beach Convention Center, FL, USA, 1-4 April 2009.
56. Kohlgraf KG, Ackermann A, Lu X et al.: Defensins attenuate cytokine responses yet enhance antibody responses to Porphyromonas gingivalis adhesins in mice. Future Microbiol. 5(1), 115-125 (2010).
57. Kinane DF, Demuth DR, Gorr SU, Hajishengallis GN, Martin MH: Human variability in innate immunity. Periodontol. 2000 45, 14-34 (2007).
58. Pingel L, Lu X, Brogden KA: Antimicrobial peptides as mucosal adjuvants. In: Virulence Mechanisms of Bacterial Pathogens. Brogden KA, Stanton TB, Cornick N et al. (Eds). ASM Press, DC, USA, 281-295 (2007).
59. Guy B: The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5, 505-517 (2007).
60. Davis SS: The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine 24(Suppl. 2), S2-S10 (2006).
61. Aucouturier J, Ascarateil S, Dupuis L: The use of oil adjuvants in therapeutic vaccines. Vaccine 24(Suppl. 2), S2-S45 (2006).
62. Myschik J, Lendemans DG, McBurney WT, Demana PH, Hook S, Rades T: On the preparation, microscopic investigation and application of ISCOMs. Micron 37, 724-734 (2006).
63. Cabeen MT, Jacobs-Wagner C: Bacterial cell shape. Nat. Rev. Microbiol. 3, 601-610 (2005).
64. Riley LW: Of mice, men, and elephants: Mycobacterium tuberculosis cell envelope lipids and pathogenesis. J. Clin. Invest. 116, 1475-1478 (2006).
65. Cloud-Hansen KA, Peterson SB, Stabb EV, Goldman WE, McFall-Ngai MJ, Handelsman J: Breaching the great wall: peptidoglycan and microbial interactions. Nat. Rev. Microbiol. 4, 710-716 (2006).
66. Freytag LC, Clements JD: Mucosal adjuvants. Vaccine 23, 1804-1813 (2005).
67. Hovav AH, Fishman Y, Bercovier H: γ interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine. Infect. Immun. 73, 250-257 (2005).
68. Barr TA, Carlring J, Heath AW: Co-stimulatory agonists as immunological adjuvants. Vaccine 24, 3399-3407 (2006).
69. Bowdish DM, Davidson DJ, Scott MG, Hancock RE: Immunomodulatory activities of small host defense peptides. Antimicrob. Agents Chemother. 49, 1727-1732 (2005).
70. Brown KL, Hancock RE: Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 18, 24-30 (2006).
71. Kruzel ML, Zimecki M: Lactoferrin and immunologic dissonance: clinical implications. Arch. Immunol. Ther. Exp. (Warsz.) 50, 399-410 (2002).
72. Chodaczek G, Zimecki M, Lukasiewicz J, Lugowski C: A complex of lactoferrin with monophosphoryl lipid A is an efficient adjuvant of the humoral and cellular immune response in mice. Med. Microbiol. Immunol. (Berl.) 195, 207-216 (2006).
73. Kurosaka K, Chen Q, Yarovinsky F, Oppenheim JJ, Yang D: Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol. 174, 6257-6265 (2005).
74. Bramwell VW, Somavarapu S, Outschoorn I, Alpar HO: Adjuvant action of melittin following intranasal immunisation with tetanus and diphtheria toxoids. J. Drug Target. 11, 525-530 (2003).
75. Fritz JH, Brunner S, Birnstiel ML et al.: The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine 22, 3274-3284 (2004).
76. An LL, Yang YH, Ma XT et al.: LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine. Leuk. Res. 29, 535-543 (2005).
77. Biragyn A, Surenhu M, Yang D et al.: Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 167, 6644-6653 (2001).
78. Tani K, Murphy WJ, Chertov O et al.: Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int. Immunol. 12, 691-700 (2000).
79. Ma XT, Xu B, An LL et al.: Vaccine with b defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses. Cancer Res. 66, 1169-1176 (2006).
80. Lillard JW Jr, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR: Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc. Natl Acad. Sci. USA 96, 651-656 (1999).
81. Brogden KA, Heidari M, Sacco RE et al.: Defensin-induced adaptive immunity in mice and its potential in preventing periodontal disease. Oral Microbiol. Immunol. 18, 95-99 (2003).
82. Brogden KA, Heidari M, Sacco RE et al.: Defensin-induced adaptive immunity in mice and its potential in preventing periodontal disease. Oral Microbiol. Immunol. 18, 95-99 (2003).
83. Wehkamp J, Salzman NH, Porter E et al.: Reduced Paneth cell a defensins in ileal Crohn's disease. Proc. Natl Acad. Sci. USA 102, 18129-18134 (2005).
84. Rivas-Santiago B, Serrano CJ, Enciso Moreno JA: Susceptibility to infectious diseases based on antimicrobial peptide production. Infect. Immun. 77, 4690-4695 (2009).
85. Aldred PM, Hollox EJ, Armour JA: Copy number polymorphism and expression level variation of the human a defensin genes DEFA1 and DEFA3. Hum. Mol. Genet. 14, 2045-2052 (2005).
86. Wehkamp J, Schmid M, Fellermann K, Stange EF: Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J. Leukoc. Biol. 77, 460-465 (2005).
87. Dork T, Stuhrmann M: Polymorphisms of the human β defensin-1 gene. Mol. Cell. Probes 12, 171-173 (1998).
88. Linzmeier RM, Ganz T: Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in a- and β defensin regions at 8p22-p23. Genomics 86, 423-430 (2005).
89. Fellermann K, Wehkamp J, Herrlinger KR, Stange EF: Crohn's disease: a defensin deficiency syndrome? Eur. J. Gastroenterol. Hepatol. 15, 627-634 (2003).
90. Boniotto M, Hazbon MH, Jordan WJ et al.: Novel hairpin-shaped primer assay to study the association of the -44 single-nucleotide polymorphism of the DEFB1 gene with early-onset periodontal disease. Clin. Diagn. Lab. Immunol. 11, 766-769 (2004).
91. Vankeerberghen A, Scudiero O, De Boeck K et al.: Distribution of human β defensin polymorphisms in various control and cystic fibrosis populations. Genomics 85, 574-581 (2005).
92. Chen Q, Book M, Fang X, Hoeft A, Stuber F: Screening of copy number polymorphisms in human β defensin genes using modified real-time quantitative PCR. J. Immunol. Methods 308, 231-240 (2006).
93. Wang G, Li X, Wang Z: APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res. 37, D933-D937 (2009).
94. Wang Z, Wang G: APD: the antimicrobial peptide database. Nucleic Acids Res. 32, D590-D592 (2004).
95. Krisanaprakornkit S, Weinberg A, Perez CN, Dale BA: Expression of the peptide antibiotic human β defensin 1 in cultured gingival epithelial cells and gingival tissue. Infect. Immun. 66, 4222-4228 (1998).
96. Dale BA, Kimball JR, Krisanaprakornkit S et al.: Localized antimicrobial peptide expression in human gingiva. J. Periodontal Res. 36, 285-294 (2001).
97. Lu Q, Samaranayake LP, Darveau RP, Jin L: Expression of human β defensin-3 in gingival epithelia. J. Periodontal Res. 40, 474-481 (2005).
98. Nishimura M, Abiko Y, Kusano K et al.: Localization of human b defensin 3 mRNA in normal oral epithelium, leukoplakia, and lichen planus: an in situ hybridization study. Med. Electron. Microsc. 36, 94-97 (2003).
99. Mathews M, Jia HP, Guthmiller JM et al.: Production of b defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect. Immun. 67, 2740-2745 (1999).
100. Dunsche A, Acil Y, Dommisch H, Siebert R, Schroder JM, Jepsen S: The novel human β defensin-3 is widely expressed in oral tissues. Eur. J. Oral Sci. 110, 121-124 (2002).
101. Harder J, Bartels J, Christophers E, Schroder JM: Isolation and characterization of human b defensin-3, a novel human inducible peptide antibiotic. J. Biol. Chem. 276, 5707-5713 (2001).
102. Kimball JR, Nittayananta W, Klausner M, Chung WO, Dale BA: Antimicrobial barrier of an in vitro oral epithelial model. Arch. Oral Biol. 51, 775-783 (2006).
103. Claeys S, de Belder T, Holtappels G et al.: Human b defensins and Toll-like receptors in the upper airway. Allergy 58, 748-753 (2003).
104. Kutta H, Steven P, Kohla G, Tillmann B, Paulsen F: The human false vocal folds - an analysis of antimicrobial defense mechanisms. Anat. Embryol. (Berl.) 205, 315-323 (2002).
105. Wenghoefer M, Pantelis A, Dommisch H et al.: Nuclear hBD-1 accumulation in malignant salivary gland tumours. BMC Cancer 8, 290 (2008).
106. Dale BA, Tao R, Kimball JR, Jurevic RJ: Oral antimicrobial peptides and biological control of caries. BMC Oral Health 6, S13 (2006).
107. Devine DA: Antimicrobial peptides in defence of the oral and respiratory tracts. Mol. Immunol. 40, 431-443 (2003).
108. Gardner MS, Rowland MD, Siu AY, Bundy JL, Wagener DK, Stephenson JL: Comprehensive defensin assay for saliva. Anal. Chem. 81, 557-566 (2009).
109. Ghosh SK, Gerken TA, Schneider KM, Feng Z, McCormick TS, Weinberg A: Quantification of human β defensin-2 and -3 in body fluids: application for studies of innate immunity. Clin. Chem. 53, 757-765 (2007).
110. Gorr SU: Antimicrobial peptides of the oral cavity. Periodontol. 2000 51, 152-180 (2009).
111. Mizukawa N, Sugiyama K, Fukunaga J et al.: Defensin-1, a peptide detected in the saliva of oral squamous cell carcinoma patients. Anticancer Res. 18, 4645-4649 (1998).
112. Pisano E, Cabras T, Montaldo C et al.: Peptides of human gingival crevicular fluid determined by HPLC-ESI-MS. Eur. J. Oral Sci. 113, 462-468 (2005).
113. Tao R, Jurevic RJ, Coulton KK et al.: Salivary antimicrobial peptide expression and dental caries experience in children. Antimicrob. Agents Chemother. 49, 3883-3888 (2005).
114. Diamond DL, Kimball JR, Krisanaprakornkit S, Ganz T, Dale BA: Detection of b defensins secreted by human oral epithelial cells. J. Immunol. Methods 256, 65-76. (2001).
115. Puklo M, Guentsch A, Hiemstra PS, Eick S, Potempa J: Analysis of neutrophil-derived antimicrobial peptides in gingival crevicular fluid suggests importance of cathelicidin LL-37 in the innate immune response against periodontogenic bacteria. Oral Microbiol. Immunol. 23, 328-335 (2008).
116. Cole AM, Dewan P, Ganz T: Innate antimicrobial activity of nasal secretions. Infect. Immun. 67, 3267-3275 (1999).
117. Soman SS, Arathy DS, Sreekumar E: Discovery of Anas platyrhynchos avian β defensin 2 (Apl-AvBD2) with antibacterial and chemotactic functions. Mol. Immunol. 46, 2029-2038 (2009).
118. Soman SS, Nair S, Issac A et al.: Immunomodulation by duck defensin, Apl-AvBD2: in vitro dendritic cell immunoreceptor (DCIR) mRNA suppression, and B- and T-lymphocyte chemotaxis. Mol. Immunol. 46(15) 3070-3075 (2009).